Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for TPT1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TPT1 Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. Suitable for physical binding assays (SPR/BLI) and PPI screening. |
View TPT1 Products |
| Gene Delivery | TPT1 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction to study tumor reversion and p53 regulation. |
View TPT1 Products |
| Benchmark Ab | Anti-TPT1 Antibody Recombinant sequence-verified antibody for transfection validation and positive control in Western Blot/ELISA. |
View TPT1 Products |
| Validator | TPT1 siRNA Set Target-specific siRNA pool for knockdown verification in phenotypic tumor reversion assays. |
View TPT1 Products |
| Related Target A | TP53 (p53) TPT1 directly interacts with p53 and promotes its MDM2-mediated degradation; targeting TPT1 rescues p53 activity. |
View TP53 Products |
| Related Target B | MCL1 TPT1 stabilizes the anti-apoptotic protein MCL1; synergistic targeting promotes apoptosis in resistant cancer cells. |
View MCL1 Products |
| Related Target C | RHEB TPT1 acts as a guanine nucleotide exchange factor (GEF) for Rheb, a key upstream regulator of mTORC1. |
View RHEB Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Intracellular Protein-Protein Interaction (PPI) screening (e.g., TPT1-p53 or TPT1-MCL1) | High-purity recombinant TPT1 proteins expressed with precise tags, sequence-verified to ensure structural integrity for SPR/BLI. |
| Extracellular cytokine-like activity assays (Histamine-Releasing Factor function) | Endotoxin-controlled recombinant TPT1 proteins to prevent non-specific immune activation in cell-based assays. |
| Lack of reliable positive control for expression validation | Sequence-defined recombinant antibodies targeting TPT1 to serve as standardized reference controls. |
| Off-target validation and phenotypic confirmation | Pre-designed siRNA knockdown pools to confirm target-specific biological effects in disease models. |
Live TPT1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of TPT1 (also known as Translationally-Controlled Tumor Protein, or TCTP) represents a highly promising frontier in oncology and immunology. In oncology, TPT1 acts as a master regulator of "tumor reversion"—a biological process where cancer cells lose their malignant phenotype. Because TPT1 promotes the degradation of the tumor suppressor p53 and stabilizes anti-apoptotic factors like MCL1, inhibiting TPT1 has emerged as a key strategy to restore tumor suppression pathways and overcome multi-drug resistance.
The race for TPT1 therapeutics is intensifying, with major players shifting focus from traditional small molecules (such as repurposing sertraline or thioridazine) to targeted protein degraders (PROTACs) and highly specific monoclonal antibodies for extracellular indications. Beyond oncology, extracellular TPT1 acts as a cytokine-like Histamine-Releasing Factor (HRF), making it a novel target for severe allergic diseases and asthma. As first-generation therapeutic strategies advance, the next wave of R&D is targeting selective TPT1 disruption in combination with standard chemotherapies or immunotherapy.
Competitive Modality & Indication Snapshot
| Modality | Representative Strategy | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors / PROTACs | Targeting TPT1-p53 or TPT1-MCL1 PPI interface | Solid Tumors, Hematological Malignancies | In vitro binding assays (Requires high-purity TPT1 recombinant proteins for SPR/BLI screening) |
| Monoclonal Antibodies (Anti-HRF) | Neutralizing extracellular secreted TPT1 | Severe Asthma, Allergic Inflammation | Functional neutralization assays (Requires endotoxin-controlled TPT1 proteins to avoid assay artifacts) |
| RNA Therapeutics (siRNA/ASO) | Direct knockdown of intracellular TPT1 expression | Refractory Cancers, Glioblastoma | Expression validation (Requires sequence-verified lentivirus and siRNA validation tools) |